Charles Schwab Investment Management Inc. Acquires 288,926 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Charles Schwab Investment Management Inc. increased its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 17.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,940,680 shares of the company’s stock after acquiring an additional 288,926 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.69% of Recursion Pharmaceuticals worth $12,789,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. ARK Investment Management LLC increased its holdings in shares of Recursion Pharmaceuticals by 16.4% during the third quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock worth $215,949,000 after purchasing an additional 4,626,268 shares during the period. Baillie Gifford & Co. increased its stake in Recursion Pharmaceuticals by 10.5% during the 2nd quarter. Baillie Gifford & Co. now owns 26,589,936 shares of the company’s stock worth $199,425,000 after acquiring an additional 2,522,132 shares during the period. Lingotto Investment Management LLP raised its holdings in Recursion Pharmaceuticals by 69.0% in the 2nd quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company’s stock valued at $27,563,000 after acquiring an additional 1,500,000 shares in the last quarter. Ghisallo Capital Management LLC bought a new stake in shares of Recursion Pharmaceuticals during the 2nd quarter valued at $8,250,000. Finally, Perceptive Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals during the 2nd quarter worth $5,769,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on RXRX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday, November 20th. Jefferies Financial Group dropped their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. Finally, Leerink Partners cut their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Tuesday, September 3rd. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $9.25.

Insider Activity

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $6.84, for a total transaction of $78,297.48. Following the sale, the director now owns 7,109,875 shares in the company, valued at $48,631,545. This represents a 0.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Michael Secora sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $6.17, for a total transaction of $92,550.00. Following the transaction, the chief financial officer now directly owns 1,377,756 shares of the company’s stock, valued at approximately $8,500,754.52. This represents a 1.08 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 134,235 shares of company stock valued at $895,538 in the last ninety days. 15.75% of the stock is currently owned by insiders.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ:RXRX opened at $8.01 on Monday. The firm has a market capitalization of $2.30 billion, a price-to-earnings ratio of -5.24 and a beta of 0.85. The stock’s 50 day moving average is $6.61 and its 200-day moving average is $7.32. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a twelve month low of $5.60 and a twelve month high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. During the same period in the previous year, the company posted ($0.43) earnings per share. The company’s quarterly revenue was up 147.6% compared to the same quarter last year. Sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.